MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Ultragenyx Pharmaceutical Company Profile (NASDAQ:RARE)

Consensus Ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) (?)
Ratings Breakdown: 2 Hold Rating(s), 15 Buy Rating(s)
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $99.53 (96.20% upside)

Analysts' Ratings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Show:
DateFirmActionRatingPrice TargetActions
6/28/2016WedbushReiterated RatingOutperform$92.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/28/2016Bank of AmericaInitiated CoverageBuy$72.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2016Canaccord GenuityReiterated RatingBuy$120.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Morgan StanleyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016JMP SecuritiesReiterated RatingBuy$80.00 -> $84.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Jefferies GroupReiterated RatingBuy$109.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/25/2016Credit SuisseReiterated RatingBuy$101.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016Robert W. BairdInitiated CoverageOutperform$85.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$125.00 -> $85.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/28/2016HC WainwrightReiterated RatingBuy$104.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Citigroup Inc.Lower Price Target$88.00 -> $67.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016Sterne Agee CRTInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/1/2015Stifel NicolausInitiated CoverageBuy -> Buy$125.00 -> $125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/15/2015Cowen and CompanyReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/31/2015Raymond JamesInitiated CoverageOutperform$125.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/13/2015SunTrustBoost Price TargetBuy$82.00 -> $119.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2015MLV & Co.Initiated CoverageBuy$79.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2015CRT CapitalInitiated CoverageBuy$90.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/9/2016Q1($1.29)($1.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q4($1.14)($1.42)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3($0.87)($1.03)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.63)($0.83)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q1 15($0.54)($0.63)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2015Q414($0.53)($0.52)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.46)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.42)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.37)($0.85)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/24/2014($0.38)($4.98)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($1.38)($1.13)($1.26)
Q2 20164($1.59)($1.13)($1.39)
Q3 20164($1.75)($1.26)($1.50)
Q4 20164($1.92)($1.40)($1.61)
(Data provided by Zacks Investment Research)
Dividend History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/20/2016Sunil AgarwalInsiderSell650$54.16$35,204.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Sunil AgarwalInsiderSell650$66.00$42,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Emil D KakkisCEOSell20,000$59.95$1,199,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2016Sunil AgarwalInsiderSell649$70.53$45,773.97View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2016Emil D KakkisCEOSell20,000$70.33$1,406,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/22/2016Sunil AgarwalInsiderSell650$61.45$39,942.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016Sunil AgarwalInsiderSell658$63.48$41,769.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2016Sunil AgarwalinsiderSell585$72.83$42,605.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/31/2015Emil D. KakkisCEOSell20,000$114.52$2,290,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2015Sunil AgarwalInsiderSell498$114.81$57,175.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2015Theodore Alan HuizengainsiderSell1,500$110.55$165,825.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Sunil AgarwalinsiderSell17,020$111.18$1,892,283.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2015Thomas Richard KassbergSVPSell3,334$109.70$365,739.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Shalini SharpCFOSell3,854$131.95$508,535.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2015Thomas Richard KassbergSVPSell3,334$102.12$340,468.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Shalini SharpCFOSell4,000$96.08$384,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2015Theodore Alan HuizengaInsiderSell1,500$94.80$142,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Thomas Richard KassbergSVPSell3,334$88.19$294,025.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2015Shalini SharpCFOSell4,000$62.23$248,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2015Thomas Richard KassbergSVPSell3,333$58.02$193,380.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015Shalini SharpCFOSell4,000$51.24$204,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014Shalini SharpCFOSell4,000$44.82$179,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Thomas Richard KassbergSVPSell3,333$40.22$134,053.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/4/2014William AliskiDirectorSell6,000$42.16$252,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2014Shalini SharpCFOSell4,000$44.07$176,280.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Thomas Richard KassbergSVPSell3,333$41.85$139,486.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014Thomas Richard KassbergSVPSell3,333$53.26$177,515.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014Shalini SharpCFOSell4,000$56.00$224,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Thomas Richard KassbergSVPSell3,333$54.82$182,715.06View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2014Thomas Richard KassbergSVPSell20,000$53.91$1,078,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2014Shalini SharpCFOSell4,000$53.97$215,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2014Group Holdings (Sbs) Advis TpgInsiderSell488,820$37.60$18,379,632.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/31/2014Fmr LlcInsiderBuy175,000$21.00$3,675,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2014Shalini SharpCFOBuy4,500$21.00$94,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2014Thomas Richard KassbergSVPBuy1,500$21.00$31,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2014William AliskiDirectorBuy5,000$21.00$105,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Ultragenyx Pharmaceutical (NASDAQ:RARE)
DateHeadline
06/28/16 10:51 AMUltragenyx Pharma Receives Breakthrough Therapy Designation For KRN23
06/28/16 07:41 AMUltragenyx Receives Breakthrough Therapy Designation for KRN23 in Pediatric Patients with X-Linked Hypophosphatemia - [at noodls] - NOVATO, Calif., June 28, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
06/25/16 05:28 PMStock Tracing Lower on the Week Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Engelwood Daily
06/25/16 05:28 PMPrice Target Update on Ultragenyx Pharmaceutical (NASDAQ:RARE) - Trade Calls
06/22/16 06:00 PMUltragenyx Pharmaceutical Inc (RARE) is Trading Lower on Unusual Volume for June 21 - Equities.com
06/21/16 05:35 PMLongtime Allergan Lawyer Named GC of Ultragenyx
06/21/16 05:35 PMUltragenyx Pharmaceutical : Appoints Karah Parschauer as Executive Vice President, General Counsel
06/20/16 07:30 AMUltragenyx Appoints Karah Parschauer as Executive Vice President, General Counsel - [GlobeNewswire] - NOVATO, Calif., June 20, 2016-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has appointed ...
06/17/16 02:52 PMChief Medical Officer Resignation Will Not Affect Ultragenyx's Catalyst-Rich Timeline - After Thursday's close, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) noted in its 8-k form about CMO Sunil Agarwal's resignation. The decision is effective August 18. The reason for the move was categorized as seeking a different career path. During the imminent search process for a new chief medical officer, CEO Emil Kakkis will lead the development leadership team. Taking into consideration management's report, according to which no changes took place concerning clinical and regulatory timelines, Canaccord Genuity still predicts multiple catalysts from the company's diverse pipeline. This pipeline includes clinical data and/or regulatory decisions ...Full story available on Benzinga.com
06/17/16 08:46 AMUltragenyx, Takeda To Develop Drugs For Rare Genetic Diseases
06/16/16 06:16 PMUltragenyx Pharma (RARE) CMO to Resign - StreetInsider.com
06/16/16 03:40 PMULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Other Events -
06/15/16 03:03 PMULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/15/16 10:35 AMJMP Securities Maintains Ultragenyx Pharmaceutical Inc to Market Outperform with Price Target $84.00 - Trade Calls
06/13/16 05:37 PMLeerink Raises Ultragenyx Pharma's Price Target On Confidence In MPS 7 Treatment
06/13/16 09:00 AMActive Watch List: Cliffs Natural Resources (NYSE:CLF), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Gerdau ... - KC Register
06/11/16 08:55 AMUltragenyx Pharmaceutical Inc (RARE) Drops 7.62% on June 09 - Equities.com
06/10/16 03:07 PMULTRAGENYX PHARMACEUTICAL INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of E -
06/09/16 09:01 AMAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (NASDAQ: RARE) and Zimmer Biomet ... - Markets.co
06/08/16 06:31 PMULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE) Financial Condition Compared to S&P 500 - CML News
06/07/16 06:15 PMBRIEF-Ultragenyx, Takeda enter into collaboration to develop, commercialize therapies for rare genetic diseases - Reuters
06/07/16 08:48 AMUltragenyx Pharmaceutical Inc.: Ultragenyx and Takeda enter into a Collaboration to Develop and Commercialize ... - The Wall Street Transcript
06/07/16 06:08 AMUltragenyx and Takeda enter into a Collaboration to Develop and Commercialize Therapies for Rare Genetic Diseases - [at noodls] - Ultragenyx to license and develop one or more product candidates from Takeda Takeda to make equity investment in Ultragenyx to fund development NOVATO, Calif. and OSAKA, Japan, June 07, 2016 (GLOBE NEWSWIRE) ...
06/06/16 09:45 AMAfter Last Week What Do Analysts Think Of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) - Share Trading News
06/04/16 06:04 PMUltragenyx Pharmaceutical Inc (RARE) is Trading Higher on Unusual Volume for June 02 - Equities.com
06/02/16 06:29 PMStock Review and Earnings Check on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - HNN - Stock Review and Earnings Check on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)HNNCurrently, sell-side analysts are expecting Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to report quarterly EPS of $-1.45. The company's next earnings report is expected to be published on or around 2016-08-11 for the period ending on 2016-06-30.and more »
06/02/16 06:29 PMBroker Watchlist: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) - Share Trading News - Broker Watchlist: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)Share Trading News07/09/2015 – JMP Securities began new coverage on Ultragenyx Pharmaceutical Inc giving the company a “market outperform” rating. They now have a USD 119 price target on the stock. The share price of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) ...
06/01/16 06:38 PMAnalyst Recommendations on These Stocks: Vantiv, Inc. (NYSE:VNTV), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Beacon Chronicle - Beacon ChronicleAnalyst Recommendations on These Stocks: Vantiv, Inc. (NYSE:VNTV), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Beacon ChronicleAccording to the Analysts, the Low Estimate Earnings of the current Quarter is -$1.59 whereas, High Estimate is -$1.27. The Previous Year EPS of this Quarter is -$0.83. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) currently has High Price Target of $125.and more »
06/01/16 03:57 PMUltragenyx Pharmaceutical, Inc. :RARE-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
06/01/16 07:45 AMUltragenyx Pharmaceutical (RARE) Jumps: Stock Up 6.6% -
06/01/16 07:43 AMUltragenyx to Present at Upcoming Investor Conferences - [at noodls] - NOVATO, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
05/31/16 06:21 PMUltragenyx Pharmaceutical Inc (RARE) Jumps 6.61% on May 31 - Equities.com - Ultragenyx Pharmaceutical Inc (RARE) Jumps 6.61% on May 31Equities.comUltragenyx Pharmaceutical Inc (RARE) was among the biggest gainers on the Russell 2000 for Tuesday May 31 as the stock popped 6.61% to $73.10, representing a gain of $4.53 per share. Some 1.29 million shares traded hands on 9,457 trades, compared ...Symantec Corporation (NASDAQ:SYMC) decreased -0.23%: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Jazz ...KC Registerall 2 news articles »
05/31/16 10:31 AMSymantec Corporation (NASDAQ:SYMC) decreased -0.23%: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Jazz ... - KC Register - Symantec Corporation (NASDAQ:SYMC) decreased -0.23%: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Jazz ...KC RegisterOn 15 May, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) provides an detailed overview of Ultragenyx Pharmaceutical Inc. scenario. Report includes top line data relating on Ultragenyx Pharmaceutical Inc. Global clinical trials scenario. This report on ...
05/30/16 01:08 PMUltragenyx Pharmaceutical Inc (NASDAQ:RARE) Broker Price Targets For The Coming Week - Share Trading News - Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 ...and more »
05/26/16 11:20 AMEarnings Review and Stock Rundown for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Wall Street Hints and News - Earnings Review and Stock Rundown for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Ultragenyx Pharmaceutical Inc.and more »
05/26/16 11:20 AMUltragenyx Pharmaceutical Incorporated (NASDAQ:RARE) Shorted Shares Increased 1.14% After Market Selling - Wall Street Hints and News - Ultragenyx Pharmaceutical Incorporated (NASDAQ:RARE) Shorted Shares Increased 1.14% After Market SellingWall Street Hints and NewsUltragenyx Pharmaceutical Inc (NASDAQ:RARE) has declined 20.00% since October 20, 2015 and is downtrending. It has underperformed by 22.09% the S&P500. Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The company ...
05/18/16 12:04 PMULTRAGENYX PHARMACEUTICAL INC. Financials -
05/10/16 05:11 AMULTRAGENYX PHARMACEUTICAL INC. Files SEC form 10-Q, Quarterly Report -
05/09/16 10:41 PMEdited Transcript of RARE earnings conference call or presentation 9-May-16 9:00pm GMT -
05/09/16 03:38 PMUltragenyx Reports First Quarter 2016 Financial Results and Corporate Update - [at noodls] - NOVATO, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
05/09/16 03:25 PMUltragenyx reports 1Q loss -
05/09/16 06:07 AMQ1 2016 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close -
05/06/16 07:44 AMUltragenyx to Present at Bank of America Merrill Lynch Healthcare Conference - [at noodls] - NOVATO, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
04/29/16 07:53 AMUltragenyx to Host Conference Call for First Quarter 2016 Financial Results and Corporate Update - [at noodls] - NOVATO, Calif., April 29, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
04/21/16 12:37 PMUltragenyx Pharmaceutical Spikes 4% Following Release Of Positive Phase 2 Data - Shares of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) gained more than 4 percent on Thursday after company reported positive interim data from a Phase 2 study. Ultragenyx Pharmaceutical focuses on the development of novel products for rare and ultra-rare diseases. The company announced that initial data from the first eight patients in a Phase 2 study of KRN23 for the treatment ...Full story available on Benzinga.com
03/14/16 10:25 AMCan Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Earnings Impress Markets? - Stocks Daily - Can Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Earnings Impress Markets?Stocks DailyAs per Zacks Group, the key to lucrative investment is buying the premium stocks in the prominent industries. When stockholders understand the tangible meaning of earnings assessment, they intend to trail the ratings to recognize the best stocks ...Ultragenyx Pharmaceutical Inc (RARE) Shares Bought by Columbus Circle InvestorsThe Vista VoiceUltragenyx Pharmaceutical Inc (RARE) Jumps 7.99% on March 11Equities.comStock in Upward Trend: Ultragenyx Pharmaceutical Inc.( NASDAQ:RARE )WallStreet.orgSmallCapWired.com -Business Standard Tribune -Franklin Independentall 9 news articles »
03/02/16 03:05 PMUltragenyx to Present at the Cowen and Company 36th Annual Health Care Conference - [GlobeNewswire] - NOVATO, Calif., March 02, 2016-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini ...
03/01/16 07:30 AMUltragenyx Announces Data Presentations of rhGUS and rhPPCA at 12th Annual WORLD Symposium™ - [GlobeNewswire] - NOVATO, Calif., March 01, 2016-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced upcoming presentations ...
02/25/16 03:05 PMUltragenyx Reports Fourth Quarter 2015 and Full-Year 2015 Financial Results and Corporate Update - [GlobeNewswire] - NOVATO, Calif., Feb. 25, 2016-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results ...
02/25/16 06:07 AMQ4 2015 Ultragenyx Pharmaceutical Inc Earnings Release - After Market Close -
About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical logoUltragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RARE
  • CUSIP:
Key Metrics:
  • Previous Close: $47.26
  • 50 Day Moving Average: $62.48
  • 200 Day Moving Average: $70.06
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.94B
  • Current Quarter EPS Consensus Estimate: $-5.84 EPS
Additional Links:
Ultragenyx Pharmaceutical (NASDAQ:RARE) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha